ESMO E-Learning: Prognostic and Predictive Biomarkers in Head & Neck Cancer
- To provide a general overview of the value and development of different biomarkers across different types of head and neck cancers
- To provide an update on the prognostic status of different biomarkers in head and neck cancers
- To provide an update on the predictive status of different biomarkers in head and neck cancers
|Title||Duration||Content||CME Points||CME Test|
|Prognostic and Predictive Biomarkers in Head & Neck Cancer||25 min.||43 slides||1||Take Test|
This E-learning module provides a state of the science of biomarkers in different types of head and neck cancers. The authors elaborate on the role and current utilisation of Epstein Barr virus DNA, human papilloma virus, PET imaging, hypoxia, Epidermal growth factor receptor, TP53 Gene mutation, gene expression profiles, and immune-checkpoint related biomarkers.
This module is particularly useful because it provides a summary of all the different biomarkers in use or under investigation in head and neck cancer, representing a rare comprehensive educational material on this subject.
The authors provide an update on viral oncogenic mechanisms, molecular, genetic and immune-related biomarkers, as well as biomarkers in patients with precancerous lesions that have an increased risk of developing into cancer.
For each of the biomarkers covered, the authors give a basic description of their implicated involvement in disease, potential prognostic and predictive roles, as well as future research directions. The relevant studies contributing to the current knowledge for each Biomarker are presented as are those relevant to the use of the biomarkers in clinical practice or which may lead to future research opportunities.
The module focuses on both established and emerging biomarkers that are most relevant for nasopharyngeal carcinoma and squamous cell cancers of the head and neck, which include primary sites in the oral cavity, oropharynx, hypopharynx and larynx. Applications and limitations of currently established biomarkers are discussed along with examples of biomarkers in development.
As reflected by the multiple sites and histologies of head and neck cancers, the molecular characteristics and clinical outcomes for these malignancies vary widely. The authors summarise the current efforts in biomarker development and utilisation that are vital for a more personalised approach to therapy in patients with head and neck cancer.
Dr Licitra has reported consultant/advisory role with Eisai, BMS, MSD, Merck-Serono, Boehringer Ingelheim, Debiopharm, Sobi, Novartis, Astra Zeneca, Bayer and Roche. She has received travel grants from Merck-Serono, Debiopharm, Sobi and Bayer.
She has also reported research funds received by her institution from Eisai, MSD, Merck-Serono, Boehringer Ingelheim, Novartis, Astra Zeneca and Roche.
Dr Alfieri has reported no conflicts of interest.